Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Equinor in connection with its investment in Medfield Diagnostics
Mandate

Vinge advised Equinor in connection with its investment in Medfield Diagnostics

November 21, 2018 Capital Markets and Public M&A

Vinge advised Equinor Technology Ventures AS (”Equinor”) in connection with its acquisition in Medfield Diagnostics Aktiebolag (publ) (“Medfield”).

The investment will be made through a directed issue to Equinor as well as a rights issue of shares. Medfield is listed on Spotlight.
Equinor ASA is a global energy company with more than 20,000 employees and business in more than 30 countries. Equinor is the largest oil and gas operator in Norway, one of the largest offshore operators globally and has a growing portfolio of renewable assets in wind and solar power.

Equinor Technology Ventures AS invests in technology companies with major implementation potential in the company’s core business. Since its establishment, ETV has invested in more than 60 companies and financed over 260 product developments.

Vinge’s team consisted of Dain Hård Nevonen, Peter Sundgren, Rikard Lindahl, Amanda Knutsson and Peter Issa. 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025